Ultragenyx Pharmaceutical | RARE - Capital Social Ordinario





Capital Social Ordinario Cambio Fecha
Acadia Pharmaceuticals USD 169.18M 470K 2025-12
Agios Pharmaceuticals USD 59.34M 892K 2026-03
Alnylam Pharmaceuticals USD 133.44M 1.07M 2026-03
BioCryst Pharmaceuticals USD 213.06M 2.54M 2025-12
BioMarin Pharmaceutical USD 193.27M 969K 2026-03
Esperion Therapeutics USD 245.22M 39.79M 2025-12
Immunic USD 120.38M 21.73M 2025-12
Insmed USD 216.52M 2.27M 2026-03
Ionis Pharmaceuticals USD 165.9M 3.93M 2026-03
Karyopharm Therapeutics USD 18.31M 18.3M 2025-12
Kyowa Hakko Kirin JPY 523.49M 1000 2026-03
MacroGenics USD 63.32M 60K 2025-12
Moderna USD 391M 2M 2025-09
Neurocrine Biosciences USD 100.6M 500K 2026-03
PTC Therapeutics USD 81.47M 1.54M 2025-12
Puma Biotechnology USD 5K 0 2024-06
Regeneron Pharmaceuticals USD 105M 300K 2026-03
Sarepta Therapeutics USD 105.57M 607K 2026-03
Ultragenyx Pharmaceutical USD 98.3M 1.7M 2026-03
Vertex Pharmaceuticals USD 254.2M 200K 2026-03
Xoma USD 87K 1000 2024-06